In analysis of TTO based on parameter distributions and the valid cases, the median TTOs (Interquartile range) for SSIBs associated with semaglutide, liraglutide, dulaglutide, and exenatide were 15.5 (0.524.25, n = 18), 9.5 (0.561.5, n = 19), 35.5 (6.560.5, n = 11), and 2.5 (1.5169.5, n = 4) days, respectively (albiglutide was not included in the TTO analysis due to insufficient data)
Slow medication titration: Some dietitians in the study recommended slower dose increases of GLP-1 medications to reduce side effects, helping patients better manage symptoms like nausea while maintaining treatment adherence
Return the vial to the refrigerator immediately
GLP-1 medications slow gastric emptying and reduce appetite, which typically lowers overall food intake